



The power of combining organic and inorganic chemistry.

800 Raymond Stotzer Parkway
Suite 2011-A
College Station, Texas 77843
www.framergy.com



Fast Facts

Founders:	J.M.Ornstein Hong-Cai "Joe" Zhou
Date Founded:	2011
Employees:	2
Headquarters:	College Station, TX
Revenue:	N/A
University:	Texas A&M University
Federal Funding Agency:	Department of Energy (Advanced Research Projects Agency) National Science Foundation
Initial Research Funding:	\$1.5M

Framergy™ is commercializing a comprehensive toolbox of uniquely-designed enabling materials that function as reliable, high-volume, high-quality, low-cost products for clean energy and other applications.

Metal organic frameworks (MOFs) refers to an extensive class of crystalline materials with ultra-high porosity and enormous internal surface area. MOFs are revolutionizing clean energy. With their incredible and unparalleled storage capacity, along with their extraordinary degree of variability, MOFs are the ideal energy warehouse. Framergy's intellectual property bundle includes multiple novel designs for a variety of MOFs to take form in a wide range of creations such as sponges in the abatement of greenhouse gases; storage devices for hydrogen or natural gas-fueled vehicles; vessels for carefully-controlled catalysts; and even enhancements to electromagnetic materials.

The Story Behind the Company

Framergy™ was founded in early 2011 by technology inventor Joe Zhou, Ph.D. and entrepreneur J.M. Ornstein to commercialize the groundbreaking chemistry innovations being developed in Dr. Zhou's laboratory at Texas A&M University. These discoveries, which allow for the creation of precisely designed MOFs and molecule traps, will enable industry to leverage the remarkable attributes of these materials for their clean energy and other needs. The research to develop the technologies behind framergy™ was supported in part through federal funding from the Department of Energy and National Science Foundation.



Simple. Solution.

2300 McDermott Road
Suite 200-147
Plano, TX 75025
www.macuclear.com



Fast Facts

Founders:	George Chiou, Philip G. Ralston, Jr.
Date Founded:	2006
Employees:	2
Headquarters:	Plano, TX
Revenue:	N/A
University:	Texas A&M University
Federal Funding Agency:	National Institutes of Health
Initial Research Funding:	\$1M

MacuCLEAR™, Inc., is focused on the design and development of small molecule products for ophthalmic treatment for age-related diseases of the eye. With the use of MC-1101, a patented, topically-delivered drug developed at Texas A&M University, the company is producing innovative eye drops to treat the leading cause of blindness and vision impairment. MacuCLEAR is driving ophthalmic innovation and commercialization with their development of the first and only eye drop treatment for the dry (early) phase of Age-related Macular Degeneration (dAMD), a condition which affects around 15 million Americans and 30 million people globally.

The Story Behind the Company

MacuCLEAR was formed to commercialize MC-1101 following its discovery as a potential breakthrough dAMD treatment by Dr. George C.Y. Chiou, professor of neuroscience and experimental therapeutics in the College of Medicine at the Texas A&M University Health Science Center. Dr. Chiou also serves as professor and director of the Institute of Ocular Pharmacology. Upon discovery and protection of MC-1101 (and related compounds) for use in various ocular disease treatments, The Texas A&M University System launched MacuCLEAR-- a university-owned start-up company to capture development support and lead clinical trial efforts around MC-1101 and future generations of ocular disease therapeutics.

Since 1969, Dr. Chiou's eye-drug research has been largely supported by the National Institutes of Health (NIH), with funding for various projects coming from the National Institute of Neurological Disease and Stroke and the National Eye Institute. NIH funding has supported the basis of Dr. Chiou's research and commercialization of treatments for glaucoma, macular edema, diabetic retinopathy, as well as dAMD.



**SPARKING
ECONOMIC
GROWTH 2.0**

The graphic has a blue background with white and yellow light streaks. The text is in a bold, sans-serif font. Below the main title, there is a smaller line of text in orange and white.

Companies Created from
Federally Funded University
Research Fueling American
Innovation and Economic Growth

6575 West Loop South, Suite 200

Bellaire, TX 77401

<http://accedent.com/>

Fast Facts

Founders:	Jeremy Mao
Date Founded:	2007
Employees:	35
Headquarters:	Bellaire, TX
Revenue:	N/A
University:	University of Illinois at Chicago
Federal Funding Agency:	National Institutes of Health (National Institute of Dental and Craniofacial Research)
Initial Research Funding:	\$1.3M

Based in Houston, TX, OrthoAccel® Technologies, Inc. is a privately held, medical device company focused on developing, manufacturing and marketing innovative technologies to enhance dental care and orthodontic treatment. The company's first product, the AcceleDent™ System, is designed to accelerate the rate of tooth movement for patients wearing braces. AcceleDent™ relies on the application of cyclic forces (sometimes described as "pulsing" or "vibratory" forces) in combination with standard orthodontics to move teeth in bone faster via accelerated bone remodeling. The removable device is used just 20 minutes per day as a complement to braces to accelerate tooth movement. Gentle micro vibrations stimulate local bone biology to increase remodeling. This allows teeth to move 38 percent to 50 percent faster. OrthoAccel® has been selling the AcceleDent™ System outside the United States since October 2009. AcceleDent™ received FDA clearance in November 2011 and is now available in the United States.

The Story Behind the Company

The foundation for the AcceleDent™ System was based on groundbreaking research started at the University of Illinois at Chicago and continued at Columbia University by Professor Dr. Jeremy Mao on the use of biomechanical forces to induce bone growth in intramembranous bones, such as those found in the human jaw. This foundational work led to the demonstration that the application of pulsating, low magnitude forces to dentation and surrounding bone accelerates orthodontic tooth movement through enhanced bone remodeling.

The initial research that spurred the development of the AcceleDent™ System was conducted with the support of a \$1.3 million grant awarded by the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health.